Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379346242> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W4379346242 endingPage "e23541" @default.
- W4379346242 startingPage "e23541" @default.
- W4379346242 abstract "e23541 Background: Malignant perivascular epithelioid cell tumor (PEComa) is a rare aggressive sarcoma, with no approved treatment in Europe, while the mechanistic target of rapamycin (mTOR) inhibitor nab-sirolimus has been approved in US. In Europe, an expanded access program is available for patients with advanced or metastatic PEComa. Methods: We retrospectively collected data of patients with advanced/metastatic PEComa treated at our institution from December 2020 through 3 rd February 2023 with nab-sirolimus. Nab-sirolimus was administered as an intravenous infusion over 30 minutes at a dosage of 100 mg/m2 on days 1 and 8 of each 21-day cycle. Results: At the time of this analysis, 10 patients were treated with nab-sirolimus and 8 are evaluable for response. Of them, 4 patients received nab-sirolimus as their first mTOR inhibitor therapy, while 4 had already received another mTOR inhibitor, being discontinued for PD. Amongst patients not pretreated with mTOR inhibitors, 2/4 had a PR as their best response, 1/4 obtained SD and 1/4 obtained PD. Amongst patients pretreated with another mTOR inhibitor, all but 1 obtained PD as their best response and 1/4 had SD. The majority of nab-sirolimus-related adverse events were grade 1 or 2 and were manageable for long-term treatment. No grade 4 treatment-related adverse events were observed. Amongst the 10 patients treated with nab-sirolimus, tumor profiling is available for 6 patients, being ongoing for the other 4. Conclusions: nab-Sirolimus is active in patients with malignant PEComa. Activity is mainly confined to those not already treated with other mTOR inhibitors." @default.
- W4379346242 created "2023-06-05" @default.
- W4379346242 creator A5009158742 @default.
- W4379346242 creator A5019787409 @default.
- W4379346242 creator A5040210154 @default.
- W4379346242 creator A5046159238 @default.
- W4379346242 creator A5046721152 @default.
- W4379346242 creator A5053619716 @default.
- W4379346242 creator A5054968300 @default.
- W4379346242 creator A5059276608 @default.
- W4379346242 creator A5063362387 @default.
- W4379346242 date "2023-06-01" @default.
- W4379346242 modified "2023-10-18" @default.
- W4379346242 title "Italian report of expanded access for nab-sirolimus in patients with malignant perivascular epithelioid cell tumor (PEComa)." @default.
- W4379346242 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.e23541" @default.
- W4379346242 hasPublicationYear "2023" @default.
- W4379346242 type Work @default.
- W4379346242 citedByCount "0" @default.
- W4379346242 crossrefType "journal-article" @default.
- W4379346242 hasAuthorship W4379346242A5009158742 @default.
- W4379346242 hasAuthorship W4379346242A5019787409 @default.
- W4379346242 hasAuthorship W4379346242A5040210154 @default.
- W4379346242 hasAuthorship W4379346242A5046159238 @default.
- W4379346242 hasAuthorship W4379346242A5046721152 @default.
- W4379346242 hasAuthorship W4379346242A5053619716 @default.
- W4379346242 hasAuthorship W4379346242A5054968300 @default.
- W4379346242 hasAuthorship W4379346242A5059276608 @default.
- W4379346242 hasAuthorship W4379346242A5063362387 @default.
- W4379346242 hasConcept C118441373 @default.
- W4379346242 hasConcept C126322002 @default.
- W4379346242 hasConcept C183713625 @default.
- W4379346242 hasConcept C185592680 @default.
- W4379346242 hasConcept C190283241 @default.
- W4379346242 hasConcept C197934379 @default.
- W4379346242 hasConcept C204232928 @default.
- W4379346242 hasConcept C2777921159 @default.
- W4379346242 hasConcept C2910136248 @default.
- W4379346242 hasConcept C55493867 @default.
- W4379346242 hasConcept C71924100 @default.
- W4379346242 hasConcept C86554907 @default.
- W4379346242 hasConceptScore W4379346242C118441373 @default.
- W4379346242 hasConceptScore W4379346242C126322002 @default.
- W4379346242 hasConceptScore W4379346242C183713625 @default.
- W4379346242 hasConceptScore W4379346242C185592680 @default.
- W4379346242 hasConceptScore W4379346242C190283241 @default.
- W4379346242 hasConceptScore W4379346242C197934379 @default.
- W4379346242 hasConceptScore W4379346242C204232928 @default.
- W4379346242 hasConceptScore W4379346242C2777921159 @default.
- W4379346242 hasConceptScore W4379346242C2910136248 @default.
- W4379346242 hasConceptScore W4379346242C55493867 @default.
- W4379346242 hasConceptScore W4379346242C71924100 @default.
- W4379346242 hasConceptScore W4379346242C86554907 @default.
- W4379346242 hasIssue "16_suppl" @default.
- W4379346242 hasLocation W43793462421 @default.
- W4379346242 hasOpenAccess W4379346242 @default.
- W4379346242 hasPrimaryLocation W43793462421 @default.
- W4379346242 hasRelatedWork W1878063970 @default.
- W4379346242 hasRelatedWork W1972972139 @default.
- W4379346242 hasRelatedWork W2283392268 @default.
- W4379346242 hasRelatedWork W2320899984 @default.
- W4379346242 hasRelatedWork W2527774606 @default.
- W4379346242 hasRelatedWork W2543104619 @default.
- W4379346242 hasRelatedWork W2944857996 @default.
- W4379346242 hasRelatedWork W2974313871 @default.
- W4379346242 hasRelatedWork W3161219116 @default.
- W4379346242 hasRelatedWork W2781008247 @default.
- W4379346242 hasVolume "41" @default.
- W4379346242 isParatext "false" @default.
- W4379346242 isRetracted "false" @default.
- W4379346242 workType "article" @default.